Pharma and healthcare: sector news on Friday 13 November 2026
Average tone +1.0 (neutral) across 5 companies with relevant coverage, from 28 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +4.2 | 14 | Coverage focused on GSK's patent wins against Pfizer and BioNTech, including a wide injunction, plus a settled dispute with Moderna and a rise in the shares. |
| AstraZeneca | +5.3 | 8 | Coverage was mostly positive, led by the acquisition of a St. |
| Smith & Nephew | −5.7 | 3 | Coverage centred on RBC Capital Markets cutting its price target on Smith & Nephew while keeping a Sector Perform rating, following a further trim to company guidance. |
| Convatec | +0.7 | 2 | Coverage was light, covering a small share price rise and the planned handover of the finance chief role to Jill McConnell. |
| Haleon | +0.5 | 1 | Coverage was thin, with only a routine report of Haleon's share price during Thursday trading. |
Strongest stories in the sector
- +10.0 Patent dispute resolved with wide-reaching injunction in company's favour
- +9.2 Won injunction covering many countries in vaccine litigation
- −8.7 Target lowered after company again reduced its outlook; weak earnings trajectory.}
- +8.3 Positive kidney trial result for a rare-disease drug.
- +7.5 Buys a small biotech, adding to its research capabilities.
- +6.7 Described as undervalued and worth owning.
- +5.8 Pipeline progress coverage framed positively.
- +5.8 Valuation commentary suggests shares still have room despite strong rally
- −5.3 Broker reduced price target while keeping a middling rating.}
- +5.0 Only partly successful outcome in patent court dispute
- +5.0 Licensing arrangement with Moderna seen as valuable for patent position
- +5.0 Shares rose and beat the wider market
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.